337 related articles for article (PubMed ID: 14574773)
1. [Elderly patients, classical monoamine oxidase inhibitors and intercurrent somatic diseases].
Oostervink F; Bouvy PF; Touw DJ
Ned Tijdschr Geneeskd; 2003 Oct; 147(40):1937-40. PubMed ID: 14574773
[TBL] [Abstract][Full Text] [Related]
2. Tranylcypromine withdrawal phenomena.
Halle MT; Dilsaver SC
J Psychiatry Neurosci; 1993 Jan; 18(1):49-50. PubMed ID: 8461282
[TBL] [Abstract][Full Text] [Related]
3. [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression].
Nolen WA
Ned Tijdschr Geneeskd; 2003 Oct; 147(40):1940-3. PubMed ID: 14574774
[TBL] [Abstract][Full Text] [Related]
4. [Abuse of the monoamine oxidase (MAOI) inhibitors as antidepressive drugs: a critical review].
García-Campayo JJ; Sanz-Carrillo C; Ferrández Payo M
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1995; 23(4):217-22. PubMed ID: 7484306
[TBL] [Abstract][Full Text] [Related]
5. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.
Ketter TA; Post RM; Parekh PI; Worthington K
J Clin Psychiatry; 1995 Oct; 56(10):471-5. PubMed ID: 7559374
[TBL] [Abstract][Full Text] [Related]
6. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression.
Feighner JP; Herbstein J; Damlouji N
J Clin Psychiatry; 1985 Jun; 46(6):206-9. PubMed ID: 3997787
[TBL] [Abstract][Full Text] [Related]
7. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
Adli M; Pilhatsch M; Bauer M; Köberle U; Ricken R; Janssen G; Ulrich S; Bschor T
Pharmacopsychiatry; 2008 Nov; 41(6):252-7. PubMed ID: 19067263
[TBL] [Abstract][Full Text] [Related]
8. Adverse consequences of fluoxetine-MAOI combination therapy.
Feighner JP; Boyer WF; Tyler DL; Neborsky RJ
J Clin Psychiatry; 1990 Jun; 51(6):222-5. PubMed ID: 2347858
[TBL] [Abstract][Full Text] [Related]
9. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
Volz HP; Gleiter CH; Möller HJ
Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
[TBL] [Abstract][Full Text] [Related]
10. Withdrawal from high-dose tranylcypromine.
Eyer F; Jetzinger E; Pfab R; Zilker T
Clin Toxicol (Phila); 2008 Mar; 46(3):261-3. PubMed ID: 18344110
[TBL] [Abstract][Full Text] [Related]
11. Refractory depression treated with high doses of monoamine oxidase inhibitor.
Guze BH; Baxter LR; Rego J
J Clin Psychiatry; 1987 Jan; 48(1):31-2. PubMed ID: 3804984
[TBL] [Abstract][Full Text] [Related]
12. Acute cardiovascular response to monoamine oxidase inhibitors: a prospective assessment.
Keck PE; Vuckovic A; Pope HG; Nierenberg AA; Gribble GW; White K
J Clin Psychopharmacol; 1989 Jun; 9(3):203-6. PubMed ID: 2738182
[TBL] [Abstract][Full Text] [Related]
13. 'Spontaneous' hypertensive episodes with monoamine oxidase inhibitors.
Fallon B; Foote B; Walsh BT; Roose SP
J Clin Psychiatry; 1988 Apr; 49(4):163-5. PubMed ID: 3281932
[TBL] [Abstract][Full Text] [Related]
14. Brofaromine in non-endogenous major depressed inpatients--results of a preliminary dose-finding trial versus tranylcypromine.
Volz HP; Heimann H; Bellaire J; Laux G; Möller HJ
Pharmacopsychiatry; 1994 Jul; 27(4):152-8. PubMed ID: 7972347
[TBL] [Abstract][Full Text] [Related]
15. Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors.
Kennedy SH
J Psychiatry Neurosci; 1997 Mar; 22(2):127-31. PubMed ID: 9074307
[TBL] [Abstract][Full Text] [Related]
16. Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.
Beasley CM; Masica DN; Heiligenstein JH; Wheadon DE; Zerbe RL
J Clin Psychopharmacol; 1993 Oct; 13(5):312-20. PubMed ID: 8227489
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous hypertensive reactions with monoamine oxidase inhibitors.
Lavin MR; Mendelowitz A; Kronig MH
Biol Psychiatry; 1993 Aug; 34(3):146-51. PubMed ID: 8399806
[TBL] [Abstract][Full Text] [Related]
18. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression.
Fawcett J; Kravitz HM; Zajecka JM; Schaff MR
J Clin Psychopharmacol; 1991 Apr; 11(2):127-32. PubMed ID: 2056139
[TBL] [Abstract][Full Text] [Related]
19. Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants.
Nolen WA; Haffmans PM; Bouvy PF; Duivenvoorden HJ
J Affect Disord; 1993 Jul; 28(3):189-97. PubMed ID: 8408980
[TBL] [Abstract][Full Text] [Related]
20. The safety of switching rapidly from tricyclic antidepressants to monoamine oxidase inhibitors.
Kahn D; Silver JM; Opler LA
J Clin Psychopharmacol; 1989 Jun; 9(3):198-202. PubMed ID: 2738181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
